Moxifloxacin 莫西沙星
Basic Information
Marketing status :
Rx
Type :
Chemical
WHO ATC code :
J01MA14: Fluoroquinolones
EphMRA ATC code :
J01G1: Oral Fluoroquinolones
2012 national/regional EDL :
No/ 2 regions
2009 national/regional RDL :
Type B / 31 regions
NDRC Pricing:
Currently priced / 2010 gov. pricing list / Low-price drug list
Branded Products (Top 5):
Avelox
拜复乐
First registrant by CFDA:
Bayer Health
拜耳医药
Total registrants number:
2
92 potential new entrants
OTC Approval
| OTC (A/B) or Rx | Formulation | Specification | Usage category | Effective date | Policy | Note |
|---|---|---|---|---|---|---|
| Rx | 滴眼剂 | 五官科用药 | 2005/12/20 | 国食药监安[2005]624号 | OTC to Rx | |
| Rx | 滴眼剂 | 五官科用药 | 2005/12/20 | 国食药监安[2005]624号 | OTC to Rx | |
| Rx | 滴眼剂 | 五官科用药 | 2005/12/20 | 国食药监安[2005]624号 | OTC to Rx | |
| Rx | 滴眼剂 | 五官科用药 | 2005/12/20 | 国食药监安[2005]624号 | OTC to Rx |
Related news
The National Administration of Drugs and Medical Devices (ANMAT) has approved of the sale of Signitor (pasireotide), the first and only drug designed especifically to treat Cushing's desease, an hormonal disorde...
- 2013/12/03
The National Administration of Drugs and Medical Devices (ANMAT) has approved of the sale of Signitor (pasireotide), the first and only drug designed especifically to treat Cushing's desease, an hormonal disorde...
- 2013/12/03
Related deals
Buyer/Investor :
Fosun International Ltd,
复星国际
Target : Espirito Santo Saude 公司
Amount : 451.00 million EUR
Target : Espirito Santo Saude 公司
Amount : 451.00 million EUR
- 2014/10/10
Buyer/Investor :
Government
政府
Target : NCPC Semisyntech Pharmaceutical Co. Ltd. 华北制药集团先泰药业有限公司
Amount : 22.2 Million USD
Target : NCPC Semisyntech Pharmaceutical Co. Ltd. 华北制药集团先泰药业有限公司
Amount : 22.2 Million USD
- 2013/12/03
Clinic Pathways:
Clinical Guideline:
www.gbihealth.com
Suite 301, Building 2, 169 Mengzi Rd.
Shanghai 200023, P.R. China
(8621) 5302 2951
(8621) 5302 2950
CONTACT GBI
© 2014 GB Group Limited. All Rights Reserved.
Terms of Service
Privacy Policy